Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) – Pipeline Review, H2 2017’, provides in depth analysis on Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Infectious Disease, Oncology and Undisclosed under development targeting Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)

The report reviews Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics and enlists all their major and minor projects

The report assesses Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Bioncotech Therapeutics SL

Rigontec GmbH

Spring Bank Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Overview 6

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Companies Involved in Therapeutics Development 19

Bioncotech Therapeutics SL 19

Rigontec GmbH 19

Spring Bank Pharmaceuticals Inc 19

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Drug Profiles 21

(SB-9200 + HBV nucleoside/tides) - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

BO-112 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

inarigivir soproxil - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Oligonucleotide to Activate RIG-1 for Influenza A Virus H1N1 Infections - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Oligonucleotides to Activate DDX58 for Unspecified Indication - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

RGT-100 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

SB-44 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

SB-9400 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

SB-9941 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

SB-9946 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Dormant Products 38

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Product Development Milestones 39

Featured News & Press Releases 39

Nov 15, 2017: Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial 39

Oct 20, 2017: Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference 40

Oct 06, 2017: Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C. 41

Aug 28, 2017: Spring Bank to Present Additional Data from the First Cohort of its Ongoing SB 9200 ACHIEVE Clinical Trial at the 2017 International HBV Meeting in Washington D.C. 41

May 23, 2017: Spring Bank Pharmaceuticals Announces Top-Line Results from the Initial Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus 42

May 22, 2017: Spring Bank Pharmaceuticals to Host Conference Call to Discuss Top-Line Results from the Initial Cohort of the Phase 2a Segment of its ACHIEVE Trial 43

May 15, 2017: Spring Bank Pharmaceuticals Announces the Data Safety Monitoring Board Approves Dose Escalation of SB 9200 for the Second Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus 43

May 03, 2017: Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer 44

Jun 22, 2016: Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B 45

Apr 21, 2016: Spring Bank Pharmaceuticals Presents Data on Immunomodulatory Agent SB 9200 at the 29th International Conference on Antiviral Research 46

Apr 14, 2016: Spring Bank Pharmaceuticals Presents Data on Immunomodulatory Agent SB 9200 at the 2016 European Association for the Study of the Liver Annual Meeting 48

Mar 31, 2016: Spring Bank Pharmaceuticals to Present Results from Preclinical Studies of SB 9200 in HBV and HCV at EASL 2016 49

Feb 23, 2016: Spring Bank Pharmaceuticals Announces Grant of European Patent for SMNH Analogs Including SB 9200 50

Dec 08, 2015: Spring Bank Pharmaceuticals Reports Preclinical Data on the Use of SB 9200 with Entecavir in the Woodchuck Model of HBV 50

Nov 16, 2015: Spring Bank Pharmaceuticals Presents Positive Phase 1 Data on SB 9200 at the 2015 American Association for the Study of Liver Diseases Annual Meeting 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 18

Pipeline by Bioncotech Therapeutics SL, H2 2017 19

Pipeline by Rigontec GmbH, H2 2017 19

Pipeline by Spring Bank Pharmaceuticals Inc, H2 2017 20

Dormant Projects, H2 2017 38

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 15

Number of Products by Stage and Routes of Administration, H2 2017 15

Number of Products by Molecule Types, H2 2017 17

Number of Products by Stage and Molecule Types, H2 2017 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports